Clinical Trials
5 trialsNCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT04152018 2025-05-28
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT03549000 2024-12-13
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated